President Trump has issued an executive order requiring the MMR vaccine to be split into three separate doses administered at different medical visits. The order directs that these single-disease shots be provided once they are domestically available. This directive aims to change the standard childhood immunization schedule that has been in place for years.
White House officials note the President has expressed strong interest in this policy shift, despite previous internal pushback earlier this year. During an Oval Office signing event, the President suggested the combined vaccine carries risks when administered at once, comparing the volume to large quantities of liquid. Health Secretary Robert F. Kennedy Jr. previously appointed advisers who advocated for this overhaul of childhood immunization protocols.
Public health experts and medical professionals have raised immediate concerns regarding the feasibility and safety of this new mandate. The Centers for Disease Control and Prevention maintains there is no scientific evidence suggesting that separating the MMR vaccine provides any health benefits. Agency data indicates the current combined vaccine is safer than the diseases it prevents, and experts reiterate that the shot is not linked to autism.
Lawmakers have also challenged the order on the basis of clinical expertise. Senator Bill Cassidy, a physician and chairman of the Senate health committee, stated that the policy is incorrect and ignores the practical consequences for families. Medical experts point out that splitting the shots will necessitate more frequent pediatrician visits, which may increase costs and create logistical hurdles that lead to lower vaccination rates overall. This comes as measles cases for 2026 have already exceeded the total number of cases reported for the previous year.
Significant practical obstacles remain for this policy. Currently, separate vaccines for measles, mumps, and rubella do not exist in the marketplace. Manufacturers would need to conduct new clinical trials and undergo federal approval processes before any such products could be made available to the public. Furthermore, it remains uncertain whether health insurers will cover the increased number of medical appointments required under this new schedule.